Atlas Trials

A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)

Clinical trial NCT02428114 · COMPLETED

Trial details

NCT number
NCT02428114
Sponsor
Ottawa Hospital Research Institute
Status
COMPLETED
Study type
OBSERVATIONAL
Early Stage Breast Cancer
Start date
2015-05-01
Primary completion
2017-03-01
Enrollment
142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.